(Q35719665)

English

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

scientific article published on 2 October 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ulcerative colitis

1 reference

based on heuristic

inferred from title

author name string

W Kruis

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

G Kiudelis

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

I Rácz

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

I A Gorelov

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

J Pokrotnieks

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M Horynski

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M Batovsky

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

J Kykal

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

S Boehm

9

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

R Greinwald

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

R Mueller

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

International Salofalk OD Study Group

12

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

2 October 2008

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

233-240

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Older adult medication compliance: integrated review of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Systematic review: adherence issues in the treatment of ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Interventions for enhancing medication adherence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Medical therapy for ulcerative colitis 2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Aminosalicylates: potential antineoplastic actions in colon cancer prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

A practical guide to the management of distal ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Approximately optimal one-parameter boundaries for group sequential trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Microscopic activity in ulcerative colitis: what does it mean?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

Sulfasalazine and 5-ASA compounds

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

A Multiple Testing Procedure for Clinical Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

27 July 2018

A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

25 September 2018

Guidelines for the management of inflammatory bowel disease in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

25 September 2018

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

25 September 2018

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

25 September 2018

Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

25 September 2018

Adaptive sample size calculations in group sequential trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

25 September 2018

Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269751

25 September 2018

Nonadherence in inflammatory bowel disease: results of factor analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18832520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/18832520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance to Therapy in Patients on a Maintenance Dose of Sulfasalazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18832520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18832520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18832520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18832520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18832520

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUT.2008.154302

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35719665&oldid=1584305174"